Objective: To observe the effect of traditional Chinese medicine "Fuzheng Qingre Tonglin"prescription on rats with complicated urinary tract infection caused by extended-spectrumβ-lactamases (ESBLs)-produci...Objective: To observe the effect of traditional Chinese medicine "Fuzheng Qingre Tonglin"prescription on rats with complicated urinary tract infection caused by extended-spectrumβ-lactamases (ESBLs)-producing Escherichia coli and its possible mechanism. Methods:Specific-pathogen-free female SD rats with 7-9 weeks old were randomly divided into model group, levofloxacin group, low-dose Fuzheng Qingre Tonglin group, high-dose Fuzheng Qingre Tonglin group, levofloxacin+Fuzheng Qingre Tonglin group (n=8 in each above group), and also there was a control group with 5 rats. Each group was administered intragastrically 2 days after model establishment for 14 consecutive days. The general condition of the rats was observed. Renal pathological changes were observed by light microscopy under hematoxylin-eosin staining. The number of white blood cells and the percentage of neutral particles (NEUT%) were detected. ELISA was used for the determination of C-reactive protein (CRP), CD4+, CD8+ in the blood, and secretory immunoglobulin A (SIgA), N-acetyl-β-D-glucosidase (NAG) molecules in urine. Results: There were a large number of inflammatory cells in the kidney of the model group and the levofloxacin group. The inflammatory cells in the treatment group were significantly reduced. The NEUT% and CRP in the blood of each treatment group and the NAG in the urine were significantly lower than those in the model group (P<0.05), except levofloxacin group. Compared with the model group, except for the levofloxacin group, serum CD4 concentration and CD4/CD8 ratio in the other treatment groups were significantly decreased, and CD8 molecules were significantly increased (P<0.05). Conclusion: "Fuzheng Qingre Tonglin" can alleviate systemic and local inflammation of complicated urinary tract infections in rats. It may also have the effect of re-sensing the insensitive antibacterial drug to bacteria and may have the function of regulating immune function and protecting kidney function in rats.展开更多
Objective:To assess the efficacy of Qingre Lishi Tuihuang therapy (QLTT) for acute icteric hepatitis B infection.Methods:Eight electronic databases were searched from inception to December 2016 with no language restri...Objective:To assess the efficacy of Qingre Lishi Tuihuang therapy (QLTT) for acute icteric hepatitis B infection.Methods:Eight electronic databases were searched from inception to December 2016 with no language restrictions for reports of randomized controlled trials evaluating the effect of QLTT treating acute icteric hepatitis B.Two researchers independently extracted detailed data and assessed methodological quality.ReviewManager 5.3.0 software was used to analyze the data.Results:A total of 13 randomized controlled trials involving 2238 participants were included in this review.The methodological quality was generally poor.The results indicated that supplemented Yinchenhao decoction combined with non-specific treatments was more effective in improving the cure rate (risk ratio =1.80;95% CI 1.21-2.68) and reducing the serum levels of total bilirubin (mean difference =-29.74;95% CI-31.91 to-27.57) and aspartate aminotransferase.Other self-made prescriptions conforming to QLTT plus non-specific treatments had beneficial effect for acute icteric hepatitis B in curing this disease (risk ratio =1.48;95% CI 1.27-1.73),as well as for negative seroconversion of HBeAg (risk ratio =1.39;95% CI 1.11-1.74).Supplemented Yinchenhao decoction plus non-specific treatments was more effective than other self-made prescriptions conforming to QLTT in reducing serum total bilirubin level.Conclusion:Qingre Lishi Tuihuang therapy appears to improve effect based on non-specific treatments for the treatment of acute icteric hepatitis B.However,it is premature to draw confirmative conclusions,owing to the poor methodological quality and high clinical heterogeneity of the included trials.Further well-designed clinical randomized controlled trials with large sample sizes should be undertaken.展开更多
目的探讨清热利湿方治疗糖尿病肠病疗效及对患者生活质量的影响。方法将48例湿热内蕴证糖尿病肠病患者按随机数字表法分观察组和对照组,每组24例;两组均口服美沙拉嗪肠溶片,观察组加予清热利湿方日2次口服治疗,统计肠炎疾病量表(inflamm...目的探讨清热利湿方治疗糖尿病肠病疗效及对患者生活质量的影响。方法将48例湿热内蕴证糖尿病肠病患者按随机数字表法分观察组和对照组,每组24例;两组均口服美沙拉嗪肠溶片,观察组加予清热利湿方日2次口服治疗,统计肠炎疾病量表(inflammatory bowel disease questionnaire,IBDQ)评分及相关症状体征。结果观察组与对照组IBDQ评分各分项得分治疗后均高于治疗前,但观察组分数增加较为明显,且观察组在全身症状、肠道症状、情感功能、社会功能、总分等方面得分增加均高于对照组,在全身症状改善方面尤为显著。两组在生活质量量表(the MOS item short from health survey,SF-36)量表中生理机能(physical functioning,PF)、生理职能(role physical,RP)、活力(vitality,VT)、精神健康(mental health,MH)、整体健康(general health,GH)等方面治疗前与治疗后差异有统计学意义(均P<0.05)。观察组总有效率91.67%(22/24),两组间疗效比较差异有统计学意义(P<0.05)。两组病例均耐受良好,未见明显不良反应,1年内复发率观察组低于对照组(均P<0.05)。结论清热利湿方可以有效清热利湿,改善患者病情,是针对糖尿病肠病的一种有效治疗方案,可以提高湿热内蕴证糖尿病肠病患者的治疗有效率,明显提高患者的生活质量,值得临床进一步研究及推广。展开更多
目的观察清热除湿方治疗急性湿疹(湿热蕴结证)的效果,初步探寻其作用机制。方法选择急性湿疹患者96例,按照随机数字表法分为观察组与对照组各48例。对照组予以3%硼酸洗液外用联合可氯雷他定胶囊口服,观察组以3%硼酸洗液外用联合清热除...目的观察清热除湿方治疗急性湿疹(湿热蕴结证)的效果,初步探寻其作用机制。方法选择急性湿疹患者96例,按照随机数字表法分为观察组与对照组各48例。对照组予以3%硼酸洗液外用联合可氯雷他定胶囊口服,观察组以3%硼酸洗液外用联合清热除湿方口服,两组疗程均为2周。比较两组治疗前后症状评分(湿疹面积、瘙痒程度、湿疹形态、皮疹颜色)、湿疹面积和严重指数(EASI)评分、瘙痒视觉模拟量表(VAS)评分,并比较两组外周血嗜酸粒细胞(EOS)、白细胞介素-4(IL-4)、免疫球蛋白E(IgE)含量和白细胞介素-22(IL-22)mRNA、芳香烃受体(AhR)m RNA相对表达量,并比较两组治疗总有效率。结果治疗后观察组症状评分、EASI评分、瘙痒VAS评分均低于对照组(P<0.05),外周血EOS、IL-4、IgE含量及IL-22 m RNA、AhR m RNA相对表达量均低于对照组(P<0.05);观察组总有效率为93.75%,显著高于对照组的77.08%(P<0.05)。结论清热除湿方可有效缓解病情,减轻临床治疗症状,降低治疗外周血EOS、IL-4、IgE含量,治疗急性湿疹(湿热蕴结证)效果显著,其机制可能与降低IL-22 m RNA、AhR m RNA表达有关。展开更多
基金This study was supported by Luzhou Science and Technology Bureau (Grant 2017LZXNYD-T09)
文摘Objective: To observe the effect of traditional Chinese medicine "Fuzheng Qingre Tonglin"prescription on rats with complicated urinary tract infection caused by extended-spectrumβ-lactamases (ESBLs)-producing Escherichia coli and its possible mechanism. Methods:Specific-pathogen-free female SD rats with 7-9 weeks old were randomly divided into model group, levofloxacin group, low-dose Fuzheng Qingre Tonglin group, high-dose Fuzheng Qingre Tonglin group, levofloxacin+Fuzheng Qingre Tonglin group (n=8 in each above group), and also there was a control group with 5 rats. Each group was administered intragastrically 2 days after model establishment for 14 consecutive days. The general condition of the rats was observed. Renal pathological changes were observed by light microscopy under hematoxylin-eosin staining. The number of white blood cells and the percentage of neutral particles (NEUT%) were detected. ELISA was used for the determination of C-reactive protein (CRP), CD4+, CD8+ in the blood, and secretory immunoglobulin A (SIgA), N-acetyl-β-D-glucosidase (NAG) molecules in urine. Results: There were a large number of inflammatory cells in the kidney of the model group and the levofloxacin group. The inflammatory cells in the treatment group were significantly reduced. The NEUT% and CRP in the blood of each treatment group and the NAG in the urine were significantly lower than those in the model group (P<0.05), except levofloxacin group. Compared with the model group, except for the levofloxacin group, serum CD4 concentration and CD4/CD8 ratio in the other treatment groups were significantly decreased, and CD8 molecules were significantly increased (P<0.05). Conclusion: "Fuzheng Qingre Tonglin" can alleviate systemic and local inflammation of complicated urinary tract infections in rats. It may also have the effect of re-sensing the insensitive antibacterial drug to bacteria and may have the function of regulating immune function and protecting kidney function in rats.
基金The study was partially supported by Chinese National Natural Science Foundation Project(81373886).We really appreciate Mei Han,Centre for Evidence-Based Chinese Medicine,Beijing University of Chinese Medicine,for her suggestions in data synthesis.
文摘Objective:To assess the efficacy of Qingre Lishi Tuihuang therapy (QLTT) for acute icteric hepatitis B infection.Methods:Eight electronic databases were searched from inception to December 2016 with no language restrictions for reports of randomized controlled trials evaluating the effect of QLTT treating acute icteric hepatitis B.Two researchers independently extracted detailed data and assessed methodological quality.ReviewManager 5.3.0 software was used to analyze the data.Results:A total of 13 randomized controlled trials involving 2238 participants were included in this review.The methodological quality was generally poor.The results indicated that supplemented Yinchenhao decoction combined with non-specific treatments was more effective in improving the cure rate (risk ratio =1.80;95% CI 1.21-2.68) and reducing the serum levels of total bilirubin (mean difference =-29.74;95% CI-31.91 to-27.57) and aspartate aminotransferase.Other self-made prescriptions conforming to QLTT plus non-specific treatments had beneficial effect for acute icteric hepatitis B in curing this disease (risk ratio =1.48;95% CI 1.27-1.73),as well as for negative seroconversion of HBeAg (risk ratio =1.39;95% CI 1.11-1.74).Supplemented Yinchenhao decoction plus non-specific treatments was more effective than other self-made prescriptions conforming to QLTT in reducing serum total bilirubin level.Conclusion:Qingre Lishi Tuihuang therapy appears to improve effect based on non-specific treatments for the treatment of acute icteric hepatitis B.However,it is premature to draw confirmative conclusions,owing to the poor methodological quality and high clinical heterogeneity of the included trials.Further well-designed clinical randomized controlled trials with large sample sizes should be undertaken.
文摘目的探讨清热利湿方治疗糖尿病肠病疗效及对患者生活质量的影响。方法将48例湿热内蕴证糖尿病肠病患者按随机数字表法分观察组和对照组,每组24例;两组均口服美沙拉嗪肠溶片,观察组加予清热利湿方日2次口服治疗,统计肠炎疾病量表(inflammatory bowel disease questionnaire,IBDQ)评分及相关症状体征。结果观察组与对照组IBDQ评分各分项得分治疗后均高于治疗前,但观察组分数增加较为明显,且观察组在全身症状、肠道症状、情感功能、社会功能、总分等方面得分增加均高于对照组,在全身症状改善方面尤为显著。两组在生活质量量表(the MOS item short from health survey,SF-36)量表中生理机能(physical functioning,PF)、生理职能(role physical,RP)、活力(vitality,VT)、精神健康(mental health,MH)、整体健康(general health,GH)等方面治疗前与治疗后差异有统计学意义(均P<0.05)。观察组总有效率91.67%(22/24),两组间疗效比较差异有统计学意义(P<0.05)。两组病例均耐受良好,未见明显不良反应,1年内复发率观察组低于对照组(均P<0.05)。结论清热利湿方可以有效清热利湿,改善患者病情,是针对糖尿病肠病的一种有效治疗方案,可以提高湿热内蕴证糖尿病肠病患者的治疗有效率,明显提高患者的生活质量,值得临床进一步研究及推广。
文摘目的观察清热除湿方治疗急性湿疹(湿热蕴结证)的效果,初步探寻其作用机制。方法选择急性湿疹患者96例,按照随机数字表法分为观察组与对照组各48例。对照组予以3%硼酸洗液外用联合可氯雷他定胶囊口服,观察组以3%硼酸洗液外用联合清热除湿方口服,两组疗程均为2周。比较两组治疗前后症状评分(湿疹面积、瘙痒程度、湿疹形态、皮疹颜色)、湿疹面积和严重指数(EASI)评分、瘙痒视觉模拟量表(VAS)评分,并比较两组外周血嗜酸粒细胞(EOS)、白细胞介素-4(IL-4)、免疫球蛋白E(IgE)含量和白细胞介素-22(IL-22)mRNA、芳香烃受体(AhR)m RNA相对表达量,并比较两组治疗总有效率。结果治疗后观察组症状评分、EASI评分、瘙痒VAS评分均低于对照组(P<0.05),外周血EOS、IL-4、IgE含量及IL-22 m RNA、AhR m RNA相对表达量均低于对照组(P<0.05);观察组总有效率为93.75%,显著高于对照组的77.08%(P<0.05)。结论清热除湿方可有效缓解病情,减轻临床治疗症状,降低治疗外周血EOS、IL-4、IgE含量,治疗急性湿疹(湿热蕴结证)效果显著,其机制可能与降低IL-22 m RNA、AhR m RNA表达有关。
